MyFitStrip LLC

Oral and systemic wellness share many common risk factors, including nitric oxide deficiency. A critical step in restoring oral and systemic health is dependent upon a functional oral microbiome capable of converting dietary prebiotic nitrate to nitric oxide. Systemic vascular health is greatly influenced by our oral health and a functional prebiotic nitrate chewing gum may provide a consumer-friendly means that optimizes a nitric oxide favorable oral microbiome. MyFitStrip observed that chewing slow-release functional chewing gums infused with a patent-pending formula of inorganic prebiotic nitrate and ascorbate shifts the oral microbiome towards a nitric oxide favorable microbiota. As important, the nitric oxide chewing gum also diminishes bacteria often associated with poor oral and systemic wellness. Aside from enhancing nitric oxide-promoting bacteria, several investigators have reported that salivary nitrate lowers the incidence of tooth decay and gum inflammation.

The U.S. Patent and Trademark Office has issued U.S. Patent Number 11,844,811 on methods and compositions for alleviating respiratory dysfunction and improving nitric oxide bioavailability to MyFitStrip LLC. Nasal airway generated nitric oxide provides an innate or natural defense against respiratory infections. Unfortunately, nitric oxide production can be compromised as we age and age-related chronic conditions and infections can suppress nitric oxide production. Boosting oral-nasal nitric oxide can elevate resistance against respiratory infections, including COVID, and elevated levels have been associated with fewer symptoms of respiratory conditions. MyFitStrip granted U.S. patent for both assessing nitric oxide with saliva test strips and improving nitric oxide levels in subjects with nitric oxide deficiencies and symptoms of respiratory conditions with dietary prebiotic nitrate and vitamin C as a means to enhance nitric oxide bioavailability.

Both oral and systemic health outcomes may improve by simply extending the residence or ‘hang time’ of prebiotic nitrate formulations in the oral cavity to improve cardiometabolic complications that exhibit dysbiosis and low nitric oxide bioavailability because of poor dietary nitrate compliance.

Clinical studies outcome may usher in new drug design and disease targeting based on nitric oxide through inhalation, immune adjuvants, and dietary approaches.

SARS-CoV-2 is emerging as a thrombotic and vascular disease targeting endothelial cells throughout the body and is particularly evident in patients with cardiometabolic comorbidities, in particular hypertension, with associated endothelial dysfunction. A hallmark of endothelial dysfunction and thrombotic events is suppressed endothelial nitric oxide synthase (eNOS) with concomitant nitric oxide deficiency. In healthy vessels, the endothelium releases the vasodilator and antithrombotic factor, nitric oxide. Whereas in injured vessels, nitric oxide is impaired contributing to hypertension and thrombus formation. Restoring nitric oxide, independent of eNOS, may counter endotheliitis and contribute to pulmonary vasodilation, antithrombotic, and direct antiviral activity.

Nitric oxide is naturally produced by the body and is best known for blood pressure homeostasis. In 1998, the Nobel Prize in Medicine was awarded to three scientists for discovering nitric oxide’s role as a key signaling molecule in the cardiovascular system. Nitric oxide is equally vital in our immune system. Viruses, mycobacteria, protozoans, bacteria, and fungi are among a growing list of microbes that are susceptible to nitric oxide. As a matter of fact, a series of in vitro studies have reported that nitric oxide inhibits SARS-CoV replication and interferes with viral infection.